Navigation Links
BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Date:9/19/2007

peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary results and analysis, that DHHS and the FDA may not agree with our analysis, that DHHS may further condition, reduce or eliminate future fun
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that after dealing with certain matters, including the appointment ... held on March 26, 2015 (the "Meeting") was adjourned, ... 8, 2015 at 11:00 a.m. ( Toronto ... been changed from that previous disclosed. The Meeting will ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Roche announced today the launch and immediate availability ... Sets for comprehensive genetic variation detection in four key human genes ... FLX Systems . The sequence-based assays offer a new solution for ... KRAS and RUNX1 genes, which are known ...
... & Burling represented AstraZeneca in its $1.26 billion ... will pay $32 per share for all of ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) AstraZeneca ... primary focus on the discovery, development and commercialization ...
... Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the ... held at 10 a.m. EDT on Tuesday, June 19, ... Donnelly Centre for Cellular and Biomolecular Research, University of ... date for the meeting is May 2, 2012. ...
Cached Biology Technology:Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 2Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 3Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Generex Announces Date of Annual Stockholders' Meeting 2Generex Announces Date of Annual Stockholders' Meeting 3
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ) ... Biometrics Market Forecast and Opportunities, 2020" report ... biometric authentication systems is projected to grow at ... The driving forces for this highly competitive ... and constant development in technology. In 2014, government ...
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... attached to the foot of an ancient Egyptian mummy ... says the scientist who tested replicas on volunteers. University ... three-part wood and leather artefact housed in the Egyptian Museum ... artificial toe on display in the British Museum, not only ...
... new University of Georgia study that is the first ... during the Deepwater Horizon Gulf of Mexico oil discharge ... hydrocarbons were emitted into the deep ocean. The authors ... 75,000 times the normcould result in small-scale zones of ...
... Moore, assistant professor of biological sciences in Louisiana ... has been named an Environmental Health Sciences, 2011 ... one of only ten 2011 Fellows from a ... of chemical and environmental science disciplines. The ...
Cached Biology News:Mummies' false toes helped ancient Egyptians walk 2Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf 2Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf 3Louisiana Tech University professor named a 2011 Environmental Health Sciences Fellow 2
Human FADD Affinity Purified Polyclonal Ab...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Biology Products: